Overview

Treatment of Androgenetic Alopecia in Men for 24 Weeks

Status:
Not yet recruiting
Trial end date:
2023-07-30
Target enrollment:
Participant gender:
Summary
A prospective, randomized, double-blind, single-center, placebo-Controlled, parallel-group study to evaluate the efficacy and safety of a new pharmaceutical form Minoxidil 5% in men after 24 weeks of treatment.
Phase:
Phase 3
Details
Lead Sponsor:
Eurofarma Laboratorios S.A.
Treatments:
Minoxidil